Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elbasvir/Grazoprevir in Treatment-Naïve HCV GT1b Patients with Non-severe Fibrosis
NCT02973503Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Jan 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of elbasvir and grazoprevir in hepatitis C virus infection, sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Sustained Viral Response 12 Weeks After Cessation of Treatment. Started Jan 2017; status: completed.
02
Drugs
elbasvirgrazoprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT02973503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973503.